Statin-Induced Autoimmune Necrotizing Myositis: A Case Report

Area of Science:

• Cardiology
• Immunology
• Neurology

Background:

• Statin therapy is a cornerstone for managing atherosclerotic cardiovascular disease (ASCVD).
• High-intensity statin dosing is crucial for maximal low-density lipoprotein cholesterol (LDL-C) reduction in coronary artery disease (CAD).
• Musculoskeletal side effects, including myopathy, are known adverse events associated with statin use, particularly at higher doses.

Observation:

• This case report details a rare instance of autoimmune-mediated necrotizing myositis.
• This condition is characterized by the development of antibodies against hydroxymethylglutaryl-coenzyme A (HMGCR) reductase.
• The HMGCR antibodies attack muscle tissue, leading to significant muscle weakness and pain.

Findings:

• Autoimmune necrotizing myositis is a rare but serious adverse effect of statin therapy.
• The presence of HMGCR antibodies is the underlying mechanism driving this myopathy.
• Clinical presentation includes pronounced muscle swelling, weakness, and pain.

Implications:

• Increased awareness of rare autoimmune myopathies is essential for clinicians prescribing statins.
• Prompt diagnosis and management, including statin cessation and immunosuppressive therapy, are critical for patient recovery.
• Further research into the immunogenic aspects of statin therapy may elucidate preventative strategies.